The 2nd annual aHUS Awareness Day will be marked on 24 September 2016. Updates from aHUS patient organizations and supporters from around the world will be …
Akari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York City
NEW YORK and LONDON, September 16th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced that Dr. …
Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
NEW YORK and LONDON, September 12th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …
Akari Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference
NEW YORK and LONDON, August 4th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …
Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria
NEW YORK and LONDON, July 13, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the …
